Trial Profile
Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
- Focus Pharmacodynamics
- Acronyms MENACWY CONJ-032_V59_71
- Sponsors GlaxoSmithKline; GSK
- 11 Nov 2022 Results (n=2669) of a pooled post analysis from two clinical studies (NCT03652610 and NCT03433482) using safety data from participants aged 10-40 years who received one dose of either liquid MenACWY-CRM or licensed MenACWY-CRM published in the Drug Safety
- 08 Oct 2021 Primary endpoint (Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) against N. meningitidis serogroup A for each vaccine group and between-groups ratios.) has been met as per results published in the Vaccine
- 08 Oct 2021 Results published in the Vaccine